Key Points
- Roivant Sciences CEO Eric Venker sold 200,000 shares on June 24 at an average price of $33.16, generating about $6.63 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- After the transaction, Venker still held 1.61 million shares valued at roughly $53.5 million, though his stake fell by about 11%. This follows two other 200,000-share sales earlier in the year.
- Roivant stock was trading around $34.07 and has been supported by mostly positive analyst coverage, with a consensus Moderate Buy rating and average price target of $33.59. The company also recently beat quarterly EPS estimates, despite weak revenue and ongoing losses.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the business's stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total value of $6,632,000.00. Following the sale, the chief executive officer owned 1,613,063 shares of the company's stock, valued at approximately $53,489,169.08. This represents a 11.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Eric Venker also recently made the following trade(s):
- On Friday, May 22nd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $30.27, for a total value of $6,054,000.00.
- On Monday, April 20th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $29.59, for a total transaction of $5,918,000.00.
Roivant Sciences Trading Up 0.1%
NASDAQ ROIV opened at $34.07 on Friday. The company has a market cap of $24.51 billion, a P/E ratio of -56.78 and a beta of 1.13. The company has a fifty day simple moving average of $29.66 and a 200 day simple moving average of $26.77. Roivant Sciences Ltd. has a 12-month low of $10.70 and a 12-month high of $34.68.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.57. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. The firm had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. During the same period last year, the firm earned ($0.29) earnings per share. Sell-side analysts predict that Roivant Sciences Ltd. will post -1.83 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the company. UBS Group AG boosted its holdings in Roivant Sciences by 570.0% during the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company's stock worth $399,080,000 after purchasing an additional 15,645,836 shares during the last quarter. Morgan Stanley increased its stake in Roivant Sciences by 31.7% in the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company's stock valued at $1,266,402,000 after buying an additional 14,036,696 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Roivant Sciences by 365.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company's stock worth $238,323,000 after buying an additional 8,621,567 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Roivant Sciences by 11,507.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company's stock worth $150,535,000 after buying an additional 6,877,348 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Roivant Sciences during the 4th quarter worth approximately $112,750,000. 64.76% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
ROIV has been the subject of a number of analyst reports. Leerink Partners set a $42.00 price target on Roivant Sciences in a research note on Thursday, May 21st. Weiss Ratings downgraded Roivant Sciences from a "sell (d)" rating to a "sell (d-)" rating in a research note on Friday, May 22nd. Sanford C. Bernstein assumed coverage on Roivant Sciences in a research note on Friday, March 20th. They issued an "outperform" rating and a $35.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $34.00 target price on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Jefferies Financial Group reaffirmed a "buy" rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $33.59.
Get Our Latest Analysis on ROIV
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
